Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice

Eonmi Kim; Sae Kwang Ku; Sumin Yang; Bong Seon Lee; Geum Jin Kim; Hyukjae Choi; Jong Sup Bae

doi:10.1080/10286020.2019.1706497

Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice

Eonmi Kim, Sae Kwang Ku, Sumin Yang, Bong Seon Lee, Geum Jin Kim, Hyukjae Choi, Jong Sup Bae

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We examined the effects of a 2,2′-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.

Original language	English
Pages (from-to)	55-72
Number of pages	18
Journal	Journal of Asian Natural Products Research
Volume	23
Issue number	1
DOIs	https://doi.org/10.1080/10286020.2019.1706497
State	Published - 2021

Keywords

Collismycin C
endothelium
HMGB1
sepsis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10286020.2019.1706497

Cite this

@article{ec8deabdb6d34f288718b6cd6d145580,

title = "Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice",

abstract = "We examined the effects of a 2,2′-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.",

keywords = "Collismycin C, endothelium, HMGB1, sepsis",

author = "Eonmi Kim and Ku, {Sae Kwang} and Sumin Yang and Lee, {Bong Seon} and Kim, {Geum Jin} and Hyukjae Choi and Bae, {Jong Sup}",

note = "Publisher Copyright: {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2021",

doi = "10.1080/10286020.2019.1706497",

language = "English",

volume = "23",

pages = "55--72",

journal = "Journal of Asian Natural Products Research",

issn = "1028-6020",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice

AU - Kim, Eonmi

AU - Ku, Sae Kwang

AU - Yang, Sumin

AU - Lee, Bong Seon

AU - Kim, Geum Jin

AU - Choi, Hyukjae

AU - Bae, Jong Sup

PY - 2021

Y1 - 2021

N2 - We examined the effects of a 2,2′-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.

AB - We examined the effects of a 2,2′-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo. Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway.

KW - Collismycin C

KW - endothelium

KW - HMGB1

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=85077912764&partnerID=8YFLogxK

U2 - 10.1080/10286020.2019.1706497

DO - 10.1080/10286020.2019.1706497

M3 - Article

C2 - 31888389

AN - SCOPUS:85077912764

SN - 1028-6020

VL - 23

SP - 55

EP - 72

JO - Journal of Asian Natural Products Research

JF - Journal of Asian Natural Products Research

IS - 1

ER -

Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this